New clinical and translational data on eblasakimab will be presented at the ISID Meeting in Tokyo, Japan. Posters will be available to view at the meeting on May 10, 2023, and will be uploaded to ASLAN’s website at this link following presentation. The first patient is expected to be enrolled in the farudodstat proof-of-concept Phase 2a study in AA in the second quarter of 2023. Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in early July 2023. Topline data from the TREK-DX trial of eblasakimab is expected in the first quarter of 2024. Topline interim data from the farudodstat Phase 2a study in AA is expected in the first quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASLN:
- ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Aslan Pharmaceuticals Ltd Adr (ASLN) Q4 Earnings Cheat Sheet
- Aslan Pharmaceuticals to hold virtual research and development day
- ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
- Aslan Pharmaceuticals announces plan to implement ADS ratio change